JBIO Aerovate Therapeutics, Inc.

Nasdaq aerovatetx.com


$ 9.39 $ -0.42 (-4.24 %)    

Friday, 17-Oct-2025 16:10:50 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 9.37
$ 9.73
$ 9.37 x 12
$ 9.78 x 4
$ 8.98 - $ 9.84
$ 6.57 - $ 13.50
156,303
na
305.71M
$ 0.84
nm
TBD
na
na ($ 0.26)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 04-25-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-25-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" ...

Core News & Articles

BTIG analyst Julian Harrison initiates coverage on Jade Biosciences (NASDAQ:JBIO) with a Buy rating and announces Price Targ...

Core News & Articles

Pursuant to the terms of the securities purchase agreement, Jade is selling an aggregate of (i) 13,368,164 shares of its common...

Core News & Articles

Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused...

Core News & Articles

Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises the price target from $17 ...

Core News & Articles

Guggenheim analyst Vamil Divan upgrades Jade Biosciences (NASDAQ:JBIO) from Neutral to Buy and announces $14 price target.

Core News & Articles

Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approxima...

Core News & Articles

Wedbush analyst Laura Chico reiterates Jade Biosciences (NASDAQ:JBIO) with a Outperform and maintains $17 price target.

Core News & Articles

Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(12.10) per share which missed the analyst consensus estimate of $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION